[ad_1]
Examination of over 800,000 mammograms reveals that black women are less likely to be screened by digital breast tomosynthesis, although the technology has been shown to be superior to traditional mammography for all women
An extensive study published in the Journal of the American College of Radiology (JACR) found racial disparities in the use of mammography screening in general, and in particular for digital breast tomosynthesis (DBT).
The study titled “Outcomes by Race in Breast Cancer Screening with Digital Breast Tomosynthesis versus Digital Mammography” reported breast cancer screening access, use and outcomes by race for 385,504 Asian, Black and Caucasian women who have underwent a total of 804,304 screening examinations at 63 breasts. imaging facilities in the United States from January 2015 to January 2019. The study was commissioned by Hologic, Inc. (Nasdaq: HOLX), a world leader in breast cancer screening technology and manufacturer of 3D Mammography ™ systems .
The results are of particular concern because research has shown that, despite a similar breast cancer incidence rate, black women are nearly 40% more likely to die from breast cancer than non-Hispanic white women.1
“Despite the fact that DBT is considered the ‘best mammogram’ for breast cancer screening and is emerging as the standard of care in the United States, our study found significant racial disparities in know who is receiving this superior technology, ”said Emily Conant, MD, study author and division chief, breast imaging, Perelman School of Medicine at the University of Pennsylvania. “The data suggests that this disparity in access, coupled with the known increase in breast cancer mortality among black women, is an urgent problem that must be addressed. Improving access to DBT may help improve the effectiveness of breast cancer screening in black women.
Improve Breast Cancer Outcomes in Black Women
The JACR review found that DBT screening improved both recall rates and cancer detection in women of all races. However, he also found that black women were less likely to receive a DBT mammogram and less likely to be screened multiple times over the five-year period than white women.
The study authors concluded that racial differences in the frequency of screening and DBT use are likely rooted in social, economic, cultural and educational disparities, and that less frequent screening of black women indicates the need. improve access and educational strategies to emphasize the importance of regular screening. .2 In addition, government and local policies and guidelines need to be improved to reduce barriers to testing, especially with DBT.
“We have long known that while breast cancer incidence rates in black and white women are comparable, black women are more likely to benefit from conventional digital mammography screening and also have longer intervals between detection, diagnosis and treatment, ”said Linda Goler Blount, MPH, study author and CEO, Black Women’s Health Imperative (BWHI). “This study highlights the sad reality of this disparity and highlights that the solution is rooted in increasing education and, most importantly, access to superior breast cancer screening modalities, such as DBT, for black women. “
Expanded access to 3D mammography technology and the possibility of earlier diagnosis through improved cancer detection are particularly relevant for black women, who develop breast cancer at a younger age than white women, are more likely to develop breast cancer. ” have late diagnoses and have lower survival rates.3.4.5
Hologic is committed to fighting racial disparities in health
Hologic, an innovative medical technology company focused primarily on improving women’s health, commissioned this research as part of an ongoing project analyzing mammograms, screening intervals, and interpretive performance in health systems across the United States.
The company recently announced a multi-year commitment to reduce disparities in breast cancer screening in black women in partnership with BWHI, the only national non-profit organization created by black women to help protect and protect. advancing the health and well-being of black women and girls through awareness and education. , and RAD-AID, a non-profit organization dedicated to ensuring equal access to radiology services for medically underserved communities.
The multi-pronged initiative includes BWHI’s POWER of Sure campaign, which examines common barriers to early detection and encourages black women to plan and attend their annual mammograms. Additionally, Hologic will fund innovative care, radiology, public education and nurse navigation at multi-regional sites selected by RAD-AID as clinical partners to provide critical screening and diagnostic breast imaging, and to provide treatment for women who might otherwise do without.
Facilities supported by this collaborative program will be equipped with Hologic’s 3D Mammography ™ system, which includes the Genius® 3D ™ mammography exam. The Genius exam is the only mammogram approved by the FDA to be superior to 2D mammography for all women, including those with dense breasts, which is common in black women.6.7,8.9
“Once again, a clinical study has proven the superiority of 3D mammography technology, the standard of care for annual breast cancer screening, for all women,” said Jennifer Meade, President of the Hologic Division, Breast and Skeletal Health Solutions. “This study also highlights the long-standing disparities that prevent black women from achieving health equity, and reinforces the need for efforts like the ones we launched late in the year. last year in partnership with BWHI and RAD-AID. “
The genius® 3D Mammography ™ Exam (also known as Genius® exam) is only available on a Hologic® 3D Mammography ™ System. It consists of a 2D and 3D® set of images, where the 2D image can be an acquired 2D image or a 2D image generated from the set of 3D ™ images. There are over 7,000 Hologic 3D Mammography ™ systems in use in the United States alone, so women have easy access to the Genius exam. To learn more, visit http://www.Genius3DNearMe.com.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving the health and well-being of women through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic, 3D, 3D Mammography, and Genius are trademarks and / or registered trademarks of Hologic, Inc. and / or its subsidiaries in the United States and / or other countries.
1 CDC, 2019. Health United States, 2018. Table 33
2 Rauscher GH, Allgood KL, Whitman S, Conant E. Disparities in mammography screening services by race / ethnicity and health insurance. J Women’s health (Larchmt). February 2012; 21 (2): 154-160.
3 American Cancer Society. 2019-20 Breast Cancer Facts and Figures. 2019.
4 Passmore SR, Williams-Parry KF, Casper E, Thomas SB. Message received: African American women and breast cancer screening. Health promotion practice. Sep 2017; 18 (5): 726-733.
5 Sighoko D, Murphy A, Irizarry B, Rauscher G, Ferrans C, Ansell D. Changes in racial disparity in breast cancer mortality in the ten US cities with the largest African American populations from 1999 to 2013; Reducing Breast Cancer Mortality in Chicago. Causes and control of cancer: CCC. 2017; 28 (6): 563-568.
6 The results of Friedewald, SM et al. “Breast cancer screening by tomosynthesis in combination with digital mammography.” JAMA 311.24 (2014): 2499-2507; a non-randomized, multi-site historical control study (13) of 454,000 screening mammograms examining the initial impact of the introduction of Hologic Selenia® Dimensions® on screening outcomes. Individual results may vary. The study found an average increase of 41% and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving 2D mammograms FFDM and 3D ™ acquired with the Hologic 3D Mammography ™ System compared to women receiving only 2D FFDM mammograms.
7 Bernardi D, Macaskill P, Pellegrini M, et. Al. Screening for breast cancer by tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared to 2D mammography alone (STORM-2): a prospective study in population. Lancet Oncol. August 2016; 17 (8): 1105-13.
8 FDA submissions P080003, P080003 / S001, P080003 / S004, P080003 / S005.
9 McCarthy A, Keller, M and. Al. Racial differences in quantitative measurements of breast area and volumetric density. Journal of the National Cancer Institute. 2016 Apr; 10.1093 / jncl / djw104.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20210219005077/en/
Contacts
Media contact:
Jane mazur
508.263.8764 (direct)
585.355.5978 (mobile)
[email protected]
Investor contact:
Michael watts
858.410.8588
[email protected]
[ad_2]
Source link